ArticleFrontiers in cardiovascular medicine2025
Impact of red blood cell transfusion volume on long-term mortality after transcatheter aortic valve replacement.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds: The relationship between red blood cell (RBC) transfusion volume and long-term survival outcomes following transcatheter aortic valve replacement (TAVR) remains inadequately characterized. This study sought to investigate the clinical impact of perioperative transfusion and identify critical thresholds for transfusion volume in predicting mortality risk after TAVR. Methods: In this retrospective cohort analysis, patients undergoing TAVR at a tertiary cardiac center between April 2012 and September 2023 were consecutively enrolled and stratified by transfusion status. Multivariate Cox regression models were employed to identify prognostic factors for mortality. The primary outcome was all-cause mortality at 1-year post-TAVR. Results: Of 1,758 included patients, 141 (8.02%) required RBC transfusions. Transfused patients exhibited higher risk profiles, female predominance, advanced age, anemia, chronic kidney disease at baseline, and increased rates of life-threatening/major bleeding, stroke, and stage 3 acute kidney injury. These patients also demonstrated elevated 30-day and 1-year mortality rates. While transfusion status ( Conclusions: Elevated transfusion volumes significantly correlate with increased long-term mortality risk in transfused TAVR recipients, primarily mediated by life-threatening hemorrhagic complications. These findings underscore the importance of implementing bleeding mitigation strategies to minimize transfusion requirements and improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.